Conotoxin-derived biomimetic coiled cone-shaped peptide as ligand for selective nanodelivery to norepinephrine transporter-expressing neuroblastoma cells
Source abstract
Abstract
Selective drug delivery is an emerging powerful strategy, which promises efficient and safer neuroblastoma treatment in contrast to conventional therapeutic modalities. Herein, we present a newly designed apoferritin nanovehicle loaded with ellipticine and decorated with conotoxin-derived biomimetic peptide YKL-6 (sequence: YKLYKLYKLYKLYKLYKLC) to target the norepinephrine transporter (hNET), which is highly expressed on neuroblastoma cells membrane. The peptide forms a coiled cone-shape forming anti-parallel beta sheets in aggregation in vitro. Molecular docking analysis suggests electrostatic interaction mediated by lysine residues against negatively charged residues of the hNET. The assembled nanovehicles show optimal biocompatibility in healthy epithelial cells and ability to deliver ellipticine into neuroblastoma cells (UKF-NB-4 and SH-SY5Y). In our analyses, we have excluded hNET-mediated endocytosis as an uptake mechanism and demonstrated the ellipticine-triggered anti-proliferative mechanisms in neuroblastoma cells via downregulation of Bcl-2, survivin and N-myc. Finally, we present a selective inhibition of neuroblastoma growth and metastasis in vivo in an ex ovo and in ovo chicken chorioallantoic membrane assay. Overall, these findings demonstrate a great leap forward in the design of biomimetic homing peptides towards possible application in neuroblastoma nanomedicine.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Neuroblastoma Research and Treatments · Cancer therapeutics and mechanisms · Lung Cancer Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Promising therapeutic targets in neuroblastoma10.1158/1078-0432.CCR-11-1939 ↗
2. Emerging and investigational therapies for neuroblastoma10.1080/21678707.2017.1304212 ↗
3. Neuroblastoma—a neural crest derived embryonal malignancy10.3389/fnmol.2019.00009 ↗
4. Neuroblastoma10.1038/nrdp.2016.78 ↗
5. Recent advances and challenges of the drugs acting on monoamine transporters10.2174/0929867325666181009123218 ↗
6. Targeting neuroblastoma cell surface proteins: recommendations for homology modeling of hNET, ALK, and TrkB10.3389/fnmol.2017.00007 ↗
7. A new targeting agent for the selective drug delivery of nanocarriers for treating neuroblastoma10.1039/C5TB00287G ↗
8. Molecular scaffolds as double-targeting agents for the diagnosis and treatment of neuroblastoma10.1002/anie.201811691 ↗
9. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates10.1016/j.jconrel.2011.10.023 ↗
10. Norepinephrine transporter-derived homing peptides enable rapid endocytosis of drug delivery nanovehicles into neuroblastoma cells10.1186/s12951-020-00654-x ↗
11. Conotoxins: structure, therapeutic potential and pharmacological applications10.2174/1381612822666151124234715 ↗
12. Inhibition of the norepinephrine transporter by the venom peptide chi-MrIA. Site of action, Na+ dependence, and structure-activity relationship10.1074/jbc.M213030200 ↗
13. 'Messy' processing of chi-conotoxin MrIA generates homologues with reduced hNET potency10.3390/md17030165 ↗
14. Discovery and development of the chi-conopeptide class of analgesic peptides10.1016/j.toxicon.2011.07.012 ↗
15. I-TASSER server: new development for protein structure and function predictions10.1093/nar/gkv342 ↗
16. GRAMM-X public web server for protein-protein docking10.1093/nar/gkl206 ↗
17. DOCKSCORE: a webserver for ranking protein-protein docked poses10.1186/s12859-015-0572-6 ↗
18. The HADDOCK web server for data-driven biomolecular docking10.1038/nprot.2010.32 ↗
19. The chick chorioallantoic membrane (CAM) assay as a three-dimensional model to study autophagy in cancer cells10.21769/BioProtoc.3290 ↗
20. Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis10.3390/ijms13089959 ↗
21. The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research
22. Preclinical models for neuroblastoma: advances and challenges10.1016/j.canlet.2020.01.015 ↗
23. Taking advantage of cellular uptake of ferritin nanocages for targeted drug delivery10.1016/j.jconrel.2020.06.026 ↗
24. Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis10.1007/s00418-008-0536-2 ↗
25. L-ferritin binding to Scara5: a new iron traffic pathway potentially implicated in retinopathy10.1371/journal.pone.0106974 ↗
26. Norepinephrine transporter-derived homing peptides enable rapid endocytosis of drug delivery nanovehicles into neuroblastoma cells10.1186/s12951-020-00654-x ↗
27. Functional analysis of novicidin peptide: coordinated delivery system for zinc via Schiff base ligand10.1021/acs.bioconjchem.8b00370 ↗
28. Apoferritin as an ubiquitous nanocarrier with excellent shelf life10.2147/IJN.S130267 ↗
29. Folic acid-mediated re-shuttling of ferritin receptor specificity towards a selective delivery of highly cytotoxic nickel(II) coordination compounds10.1016/j.ijbiomac.2018.12.128 ↗
30. Biological properties of 8-methoxypyrimido 4(1),5(1): 4,5 thieno(2,3-b) quinoline-4(3H)-one, a new class of DNA intercalating drugs
31. In vitro cytotoxicity of carbazole derivatives .5. 9-halogeno-substituted 5,11-dimethyl-6H-pyrido 3,2-b carbazoles10.1016/S0223-5234(97)87537-X ↗
32. Oxoaporphine metal complexes (Co-II, Ni-II, Zn-II) with high antitumor activity by inducing mitochondria-mediated apoptosis and S-phase arrest in HepG210.1038/srep46056 ↗
33. Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma10.15252/emmm.201911749 ↗
34. Targeting the DNA damage response for the treatment of high risk neuroblastoma10.3389/fonc.2020.00371 ↗
35. FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma10.1038/s41388-019-0912-5 ↗
36. Accelerating drug development for neuroblastoma: summary of the second neuroblastoma drug development strategy forum from innovative therapies for children with cancer and international society of paediatric oncology Europe neuroblastoma10.1016/j.ejca.2020.05.010 ↗
37. The chick embryo chorioallantoic membrane as an in vivo experimental model to study human neuroblastoma10.1002/jcp.26773 ↗
38. CDK inhibitors reduce cell proliferation and reverse hypoxia-induced metastasis of neuroblastoma tumours in a chick embryo model10.1038/s41598-019-45571-8 ↗
39. QMEAN server for protein model quality estimation10.1093/nar/gkp322 ↗
40. MolProbity: all-atom structure validation for macromolecular crystallography10.1107/S0907444909042073 ↗
41. UCSF chimera - A visualization system for exploratory research and analysis10.1002/jcc.20084 ↗
42. Guidelines for homology modeling of dopamine, norepinephrine, and serotonin transporters10.1021/acschemneuro.6b00242 ↗
43. H++: a server for estimating p K as and adding missing hydrogens to macromolecules10.1093/nar/gki464 ↗
44. Improved generalized born solvent model parameters for protein simulations10.1021/ct3010485 ↗
45. The Amber biomolecular simulation programs10.1002/jcc.20290 ↗
46. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features10.1002/bip.360221211 ↗
47. New benchmark metrics for protein-protein docking methods10.1002/prot.22987 ↗
48. Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy10.1073/pnas.1500851112 ↗
49. Site-directed conjugation of antibodies to apoferritin nanocarrier for targeted drug delivery to prostate cancer cells10.1021/acsami.6b04286 ↗
50. Localization of CdSe/ZnS quantum dots in the lysosomal acidic compartment of cultured neurons and its impact on viability: potential role of ion release10.1016/j.tiv.2012.12.016 ↗
51. Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS-ERK pathway oncogenes10.1016/j.ccell.2015.07.001 ↗
52. Accessing key steps of human tumor progression in vivo by using an avian embryo model10.1073/pnas.0408622102 ↗